SCHEMBL2368074

SCHEMBL2368074

CCCCCCCCCCCCOc1cc2nc3ccccc3nc2cc1OCCCCCCCCCCCC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 4/20 0.61
NQO2 P16083 2/20 0.52
GPBAR1 Q8TDU6 2/20 0.47
MCHR1 Q99705 2/20 0.47
MAPT P10636 2/20 0.46
LMNA P02545 2/20 0.46
CYP3A4 P08684 2/20 0.46
MEN1 O00255 1/20 0.46
NR1I2 O75469 1/20 0.46
CHRM2 P08172 1/20 0.46
ADRA2A P08913 1/20 0.46
OPRK1 P41145 1/20 0.46
HTR2B P41595 1/20 0.46
SLC6A3 Q01959 1/20 0.46
KMT2A Q03164 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
PDE5A O76074 3/20 0.46
PDE4A P27815 2/20 0.46
PDE4B Q07343 2/20 0.46
PDE4C Q08493 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12510798 1.00 TLR8 (0.61) TLR8NQO2GPBAR1MCHR1MAPT
SCHEMBL2246934 0.84 TLR8 (0.50) TLR8MCHR1MAPTLMNACYP3A4
SCHEMBL6933511 0.84 TLR8 (0.50) TLR8MCHR1MAPTLMNACYP3A4
SCHEMBL2367661 0.83 TLR8 (0.54) TLR8MCHR1MAPTLMNACYP3A4
SCHEMBL346563 0.82 TLR8 (0.64) TLR8GPBAR1MCHR1MAPTLMNA
SCHEMBL2368024 0.81 ALDH1A1 (0.56) MEN1KMT2AALDH1A1NPC1HPGD
SCHEMBL28002627 0.80 TLR8 (0.54) TLR8GPBAR1MAPTLMNACYP3A4
SCHEMBL31290761 0.80 TLR8 (0.63) TLR8GPBAR1MCHR1MAPTLMNA
SCHEMBL4250155 0.79 TLR8 (0.60) TLR8GPBAR1MCHR1MAPTLMNA
SCHEMBL30844101 0.79 TLR8 (0.60) TLR8GPBAR1MCHR1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011117830-A1 DERIVATIVES OF PHENAZINE USEFUL TO TREAT CANCER Université de la Méditerranée AIX-Marseille II (FR) 2011-09-29 WO claimed
EP-2368885-A1 Derivatives of phenazine useful to treat cancer Université de la Méditerranée (Aix-Marseille II) (FR) 2011-09-28 EP claimed
US-8552086-B2 Dental compositions including organogelators, products, and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-10-08 US disclosed
US-8552086-B2 Dental compositions including organogelators, products, and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-10-08 US disclosed
US-8445558-B2 Dental compositions including organogelators, products, and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-05-21 US disclosed
US-8445558-B2 Dental compositions including organogelators, products, and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-05-21 US disclosed
US-20130109780-A1 DENTAL COMPOSITIONS INLCUDING ORGANOGELATORS, PRODUCTS, AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-05-02 US disclosed
US-20130109780-A1 DENTAL COMPOSITIONS INLCUDING ORGANOGELATORS, PRODUCTS, AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-05-02 US disclosed
WO-2011117830-A1 DERIVATIVES OF PHENAZINE USEFUL TO TREAT CANCER Université de la Méditerranée AIX-Marseille II (FR) 2011-09-29 WO disclosed
EP-2368885-A1 Derivatives of phenazine useful to treat cancer Université de la Méditerranée (Aix-Marseille II) (FR) 2011-09-28 EP disclosed
EP-2073782-B1 DENTAL COMPOSITIONS INCLUDING ORGANOGELATORS, PRODUCTS, AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2011-07-20 EP disclosed
US-20090305196-A1 DENTAL COMPOSITIONS INCLUDING ORGANOGELATORS, PRODUCTS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2009-12-10 US disclosed
US-20090305196-A1 DENTAL COMPOSITIONS INCLUDING ORGANOGELATORS, PRODUCTS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2009-12-10 US disclosed
WO-2008033911-A2 DENTAL COMPOSITIONS INCLUDING ORGANOGELATORS, PRODUCTS, AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109780-A1 DENTAL COMPOSITIONS INLCUDING ORGANOGELATORS, PRODUCTS, AND METHODS ILK, EPM2A, PDE6G TLR8 3890/4885NQO2 2682/4885GPBAR1 4255/4885
US-20090305196-A1 DENTAL COMPOSITIONS INCLUDING ORGANOGELATORS, PRODUCTS, AND METHODS DDOST, DNA2, KRTCAP2 TLR8 4193/4885NQO2 2534/4885GPBAR1 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.